Skip to main content
EN
Caution:
At present, there are occasional discrepancies in the display of intellectual property rights holders and their representatives. We are working on a solution.
Patent Search
Details
Details for 2019734289
Up to date per 13.06.2026
Actions
Copy link to European Patent
Download Registration Print
Details
Details for 2019734289
Title / Product Name
PURINONEDERIVATE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON KREBS
Status
Deleted
Protection Type
European Patent
(AT-) Application Number
2019734289
EP Publication Number
3807278
E-Number
1515235
Language
EN
PCT Number
EP19065686
Publication Date
21.04.2021 A
31.08.2022 B1
Registration Date
31.08.2022
AT Publication Date
15.09.2022
Application Date
14.06.2019
Registration Number
-
Priorities
15.06.2018
US
201862685325 P
IPC
C07D 473/32 20060101AFI20191220BHEP
Maximum Duration of Protection
14.06.2039
Owner
Astrazeneca AB
151 85 Södertälje
SE
CANCER RESEARCH TECHNOLOGY LIMITED
Angel Building 407 St. John Street
London EC1V 4AD
GB
Representative
No representatives present
Inventor
FINLAY, Maurice, Raymond, Verschoyle
AstraZeneca UK Limited 1 Francis Crick Avenue, Cambridge Biomedical Campus
Cambridge Cambridgeshire CB2 0AA
GB
GOLDBERG, Frederick, Woolf
AstraZeneca UK Limited 1 Francis Crick Avenue, Cambridge Biomedical Campus
Cambridge Cambridgeshire CB2 0AA
GB
HOWARD, Martin, Richard
AstraZeneca UK Limited 1 Francis Crick Avenue, Cambridge Biomedical Campus
Cambridge Cambridgeshire CB2 0AA
GB
TING, Attilla, Kuan, Tsuei
AstraZeneca UK Limited 1 Francis Crick Avenue, Cambridge Biomedical Campus
Cambridge Cambridgeshire CB2 0AA
GB
see.ip - Details for PURINONEDERIVATE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON KREBS